SCHEMBL4467484

SCHEMBL4467484

Cc1c(O)c(CCC(C)C)c(C)c2c1CCC1(CCC1)O2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
LMNA P02545 2/20 0.46
TTPA P49638 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GSTP1 P09211 1/20 0.46
USP2 O75604 1/20 0.46
THRB P10828 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NR1I2 O75469 2/20 0.40
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
ALOX5 P09917 2/20 0.37
AKT1 P31749 4/20 0.34
PDPK1 O15530 1/20 0.34
PHLPP1 O60346 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464819 0.91 LMNA (0.56) MAPTLMNATTPAMEN1KMT2A
SCHEMBL5773566 0.85 MAPT (0.49) MAPTLMNATTPAMEN1KMT2A
SCHEMBL4471043 0.77 CYP3A4 (0.58) MAPTLMNATTPAMEN1KMT2A
SCHEMBL5796245 0.75 MAPT (0.49) MAPTLMNATTPAMEN1KMT2A
SCHEMBL5774081 0.75 TTPA (0.49) MAPTLMNATTPAMEN1KMT2A
SCHEMBL4468077 0.74 NR1I2 (0.37) MAPTLMNATTPAMEN1KMT2A
SCHEMBL4482568 0.73 CYP3A4 (0.41) MAPTLMNATTPAMEN1KMT2A
SCHEMBL4472749 0.73 CYP3A4 (0.43) MAPTLMNATTPAMEN1KMT2A
SCHEMBL4468647 0.72 MEN1 (0.37) MAPTMEN1KMT2ACYP2C9CYP2C19
SCHEMBL14283917 0.71 MAPT (0.73) MAPTLMNATTPAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 MAPT 4822/4885LMNA 1769/4885TTPA 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.